About ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

Website
Website
Employees
Employees
201-500 employees View all
Industry
Industry
biotechnology
Location
Location
US
Description
Information
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company Alternatives

Industry
Biotechnology
Industry
Biotechnology
Industry
Biotechnology

Frequently Asked Questions about ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

What is ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company email format?

The widely used ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company email format is {first}.{last} (e.g. [email protected]) with 81.1% adoption across the company.


What is ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company customer service number?

To contact ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company customer service number in your country click here to find.


Who is the CEO of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company?

Wu Chen Jia is the CEO of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more